In conclusion, CD8+ T cell-mediated immunotherapy in GC patients may require the modulation of suppressive CD45+CD33lowCD11bdim MDSCs to be maximally effective, in particular through the blockade of the IL-6/IL-8-arginase I axis. The gene discussed is PTPRC; the disease is gastric cancer.